Our study demonstrated that Sesn2 overexpression could attenuate oxidative stress in pathological cardiac hypertrophy via increasing Nrf2/HO-1 signaling pathway and SOD activity but decreasing the production of MDA, p67, and 4-HEN and depressing NADPH activity. The gene discussed is SESN2; the disease is cardiac hypertrophy.